
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-02-01-2012
- Volume 24
- Issue 2
Evaluating Impurities in Drugs (Part I of III)
In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products.
By Kashyap R. Wadekar, Mitali Bhalme, S. Srinivasa Rao, K. Vigneshwar Reddy, L. Sampath Kumar and E. Balasubrahmanyam
To ensure the quality of APIs and finished drug products, impurities must be monitored carefully during process development, optimization, and process changeover. The isolation, characterization, and control of impurities in pharmaceutical substances are being reviewed with greater attention based on national regulatory and international guidelines. In Part I of this article, the authors examine the different types and sources of impurities with specific examples.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
almost 14 years ago
News: FDA's Social Media Insightalmost 14 years ago
Head in the Cloudsalmost 14 years ago
Cliffhangeralmost 14 years ago
2012: A Good, Bad or Ugly Year for Servier?almost 14 years ago
Understanding Gamma Sterilisationalmost 14 years ago
Decoding the Hype and Fear of Nanomedicinesalmost 14 years ago
Pointed Debate: Expert Views on InjectablesNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.




